To The Moon

As the US earnings season approaches, Wall Street braces for potential market turbulence. It's prime time to consider positioning in sturdy blue-chip stocks for a cushion. 1. $Apple(AAPL)$ Apple's been the rockstar of blue chips, boasting a moat wider than the Grand Canyon. Its competitive edge keeps it top dog. Q2 saw a slight 4% revenue dip to $90.8bn, but diluted earnings per share held steady at $1.53. Apple's pledging $110bn for share buybacks. Service revenue soared 14% YoY, spotlighting diversification's gold. Upcoming Apple Music, Fitness+, and subscription bundles aim to hook customers for recurring revenue. Plus, Apple Intelligence, their new AI platform, promises big things. Stock's up 22%+ YTD, with a P/E of 33.9 and P/S of 9.4. Analysts flag overvaluation, targeting $220—a 6% dip. But bullish sentiment and growth prospects hint Apple's got legs for long-term gains, especially with upcoming milestones. Earnings on Aug 1; dips could be a steal. 2. $Chevron(CVX)$ Chevron's a full-spectrum energy player, with petrochemicals and plastics touching every industry. Q1 global output jumped 12%, but profits dipped to $5.4bn ($2.93/share) due to lower fuel margins and gas prices. Dividends up 8% QoQ, and $3B in buybacks. Chevron's poised for energy demand growth. Its Bunge partnership for a Louisiana oilseed plant aligns with green energy, boosting renewables by 2026. Shares up 6% since Jan, yielding 4.1%. Analysts eye $180, a 14% leap. 3. $Sanofi SA(SNY)$ Sanofi, France's healthcare giant, boasts a solid lineup of vaccines and RX drugs. Three decades of steady earnings and dividends make it a solid portfolio anchor. Sanofi's bolstering its portfolio through partnerships and acquisitions, like Inhibrx for rare diseases, set to boost revenues. A dozen Phase 3 trials due 2024-2025 keep the pipeline humming. Stock's up 1% YTD, yielding over 4%. Analysts target $58.78, nearly 18% upside. Earnings on July 25; keep an eye out.